Success Metrics

Clinical Success Rate
50.0%

Based on 5 completed trials

Completion Rate
50%(5/10)
Active Trials
8(35%)
Results Posted
120%(6 trials)
Terminated
5(22%)

Phase Distribution

Ph phase_2
8
35%
Ph phase_1
7
30%

Phase Distribution

7

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
7(46.7%)
Phase 2Efficacy & side effects
8(53.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

38.5%

5 of 13 finished

Non-Completion Rate

61.5%

8 ended early

Currently Active

8

trials recruiting

Total Trials

23

all time

Status Distribution
Active(8)
Completed(5)
Terminated(8)
Other(2)

Detailed Status

Completed5
Terminated5
Recruiting4
Active, not recruiting4
Withdrawn3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
23
Active
8
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (46.7%)
Phase 28 (53.3%)

Trials by Status

completed522%
recruiting417%
withdrawn313%
unknown29%
active_not_recruiting417%
terminated522%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT03988283Phase 1

Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors

Recruiting
NCT04331119Phase 2

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Terminated
NCT03389477Phase 2

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Active Not Recruiting
NCT02611180

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Active Not Recruiting
NCT04263181

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Active Not Recruiting
NCT07331506

Validation of the Oncoliq Test for the Early Detection of Breast Cancer.

Recruiting
NCT00353483

Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

Recruiting
NCT04643379Phase 2

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Active Not Recruiting
NCT02604563

Aging, Geriatric Syndromes and Clonal Hematopoiesis

Recruiting
NCT02630823Phase 1

MK-3475 Immunotherapy in Endometrial Carcinoma

Completed
NCT03689855Phase 2

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

Completed
NCT03199040Phase 1

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Terminated
NCT03297697

Minimal Residual Disease in Peripheral T-cell Lymphoma

Completed
NCT04372602Phase 2

Duvelisib to Combat COVID-19

Completed
NCT03063203Phase 2

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Terminated
NCT03386214Phase 1

Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

Terminated
NCT03068832Phase 1

Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors

Withdrawn
NCT02462200Phase 2

Shave Margins in Breast Conservation Therapy

Terminated
NCT04354714Phase 2

Ruxolitinib to Combat COVID-19

Withdrawn
NCT04391400

The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines

Unknown

Drug Details

Intervention Type
PROCEDURE
Total Trials
23